Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

579 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TET2 Mutation in Adult T-Cell Leukemia/Lymphoma.
Shimoda K, Shide K, Kameda T, Hidaka T, Kubuki Y, Kamiunten A, Sekine M, Akizuki K, Shimoda H, Yamaji T, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Kitanaka A. Shimoda K, et al. Among authors: tahara y. J Clin Exp Hematop. 2015;55(3):145-9. doi: 10.3960/jslrt.55.145. J Clin Exp Hematop. 2015. PMID: 26763362 Free article.
TET2 mutation in diffuse large B-cell lymphoma.
Kubuki Y, Yamaji T, Hidaka T, Kameda T, Shide K, Sekine M, Kamiunten A, Akizuki K, Shimoda H, Tahira Y, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Kitanaka A, Shimoda K. Kubuki Y, et al. Among authors: tahara y. J Clin Exp Hematop. 2017;56(3):145-149. doi: 10.3960/jslrt.56.145. J Clin Exp Hematop. 2017. PMID: 28331128 Free PMC article.
Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator.
Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Taniguchi Y, Hidaka T, Kubuki Y, Shimoda H, Marutsuka K, Sashida G, Aoyama K, Yoshimitsu M, Harada T, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Iwama A, Kitanaka A, Shimoda K. Kameda T, et al. Among authors: tahara y. Blood. 2015 Jan 8;125(2):304-15. doi: 10.1182/blood-2014-04-555508. Epub 2014 Nov 13. Blood. 2015. PMID: 25395421 Free article.
Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms.
Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Hidaka T, Kubuki Y, Sashida G, Aoyama K, Yoshimitsu M, Abe H, Miike T, Iwakiri H, Tahara Y, Yamamoto S, Hasuike S, Nagata K, Iwama A, Kitanaka A, Shimoda K. Kameda T, et al. Among authors: tahara y. Genom Data. 2015 Apr 9;4:102-8. doi: 10.1016/j.gdata.2015.04.002. eCollection 2015 Jun. Genom Data. 2015. PMID: 26484191 Free PMC article.
The clinical impact of human T-lymphotrophic virus type 1 (HTLV-1) infection on the development of adult T-cell leukemia-lymphoma (ATL) or HTLV-1-associated myelopathy (HAM) / atypical HAM after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and renal transplantation.
Kawano N, Yoshida S, Kawano S, Kuriyama T, Tahara Y, Toyofuku A, Manabe T, Doi A, Terasaka S, Yamashita K, Ueda Y, Ochiai H, Marutsuka K, Yamano Y, Shimoda K, Kikuchi I. Kawano N, et al. Among authors: tahara y. J Clin Exp Hematop. 2018 Sep 19;58(3):107-121. doi: 10.3960/jslrt.18011. Epub 2018 Aug 8. J Clin Exp Hematop. 2018. PMID: 30089749 Free PMC article. Clinical Trial.
Clinical features and treatment outcomes of opportunistic infections among human T-lymphotrophic virus type 1 (HTLV-1) carriers and patients with adult T-cell leukemia-lymphoma (ATL) at a single institution from 2006 to 2016.
Kawano N, Nagahiro Y, Yoshida S, Tahara Y, Himeji D, Kuriyama T, Tochigi T, Nakaike T, Shimokawa T, Yamashita K, Ochiai H, Marutsuka K, Mashiba K, Shimoda K, Teshima T, Kikuchi I. Kawano N, et al. Among authors: tahara y. J Clin Exp Hematop. 2019;59(4):156-167. doi: 10.3960/jslrt.18032. J Clin Exp Hematop. 2019. PMID: 31866618 Free PMC article. Clinical Trial.
Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.
Shide K, Kameda T, Yamaji T, Sekine M, Inada N, Kamiunten A, Akizuki K, Nakamura K, Hidaka T, Kubuki Y, Shimoda H, Kitanaka A, Honda A, Sawaguchi A, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Hasuike S, Yamamoto S, Nagata K, Shimoda K. Shide K, et al. Among authors: tahara y. Leukemia. 2017 May;31(5):1136-1144. doi: 10.1038/leu.2016.308. Epub 2016 Nov 3. Leukemia. 2017. PMID: 27807369 Free PMC article.
Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations.
Kubuki Y, Shide K, Kameda T, Yamaji T, Sekine M, Kamiunten A, Akizuki K, Shimoda H, Tahira Y, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Hashimoto K, Yamamoto S, Hasuike S, Hidaka T, Nagata K, Kitanaka A, Shimoda K. Kubuki Y, et al. Among authors: tahara y. Ann Lab Med. 2017 Mar;37(2):159-161. doi: 10.3343/alm.2017.37.2.159. Ann Lab Med. 2017. PMID: 28029004 Free PMC article. No abstract available.
Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis.
Shide K, Kameda T, Kamiunten A, Oji A, Ozono Y, Sekine M, Honda A, Kitanaka A, Akizuki K, Tahira Y, Nakamura K, Hidaka T, Kubuki Y, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Hasuike S, Yamamoto S, Nagata K, Ikawa M, Shimoda K. Shide K, et al. Among authors: tahara y. Blood Cancer J. 2019 Mar 29;9(4):42. doi: 10.1038/s41408-019-0202-z. Blood Cancer J. 2019. PMID: 30926777 Free PMC article.
579 results